Search Results - Eline Menu

Refine Results
  1. 1

    Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy by Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu, Elke De Bruyne

    Published in Cell Communication and Signaling (2024-06-01)
    Get full text
    Article


  2. 2

    Fueling CARs: metabolic strategies to enhance CAR T-cell therapy by Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu

    Published in Experimental Hematology & Oncology (2024-07-01)
    Get full text
    Article


  3. 3

    The Effects of Forodesine in Murine and Human Multiple Myeloma Cells by Liesbeth Bieghs, Jo Caers, Elke De Bruyne, Els Van Valckenborgh, Fiona Higginbotham, Karin Vanderkerken, Eline Menu

    Published in Advances in Hematology (2010-01-01)
    Get full text
    Article


  4. 4

    Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma by Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken, Eline Menu

    Published in Experimental Hematology & Oncology (2022-09-01)
    Get full text
    Article


  5. 5

    Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy by Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Hui Zhang, Zhongrui Liu, Eline Menu, Jinheng Wang

    Published in Advanced Science (2025-01-01)
    Get full text
    Article


  6. 6

    Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects by Lien De Beck, Sarah Melhaoui, Kim De Veirman, Eline Menu, Elke De Bruyne, Karin Vanderkerken, Karine Breckpot, Ken Maes

    Published in OncoImmunology (2018-10-01)
    Get full text
    Article


  7. 7

    Histone deacetylase inhibitors in multiple myeloma by Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken

    Published in Hematology Reports (2009-06-01)
    Get full text
    Article


  8. 8

    The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers by Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman

    Published in Frontiers in Immunology (2022-10-01)
    Get full text
    Article


  9. 9

    AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies by Niels Vandewalle, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman

    Published in Experimental Hematology & Oncology (2024-10-01)
    Get full text
    Article


  10. 10

    S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma by Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia Berkers, Jérome Moreaux, Elke De Bruyne, Eline Menu

    Published in Haematologica (2023-07-01)
    Get full text
    Article


  11. 11

    Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition by Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, Eline Menu

    Published in Haematologica (2017-07-01)
    Get full text
    Article


  12. 12

    Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma by Jo Caers, Dirk Hose, Ine Kuipers, Tomas Jan Bos, Els Van Valckenborgh, Eline Menu, Elke De Bruyne, Hartmut Goldschmidt, Ben Van Camp, Bernard Klein, Karin Vanderkerken

    Published in Haematologica (2010-01-01)
    Get full text
    Article


  13. 13

    Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma by Michiel De Coster, Lukas Hyka, Sophie De Cock, Sofie Meeussen, Zuowei Wang, Chenggong Tu, Sophie Hernot, Nick Devoogdt, Guido David, Kim De Veirman, Karin Vanderkerken, Eline Menu, Pascale Zimmermann, Elke De Bruyne

    Published in Journal of Extracellular Vesicles (2026-06-01)
    Get full text
    Article


  14. 14

    Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency by Chenggong Tu, Raphael Leblanc, Arne Van der Vreken, Marnix Koops, Stephane Audebert, Lauriane Goullieux, Sofie Meeussen, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Guido David, Tom Cupedo, Pascale Zimmermann, Eline Menu

    Published in HemaSphere (2025-08-01)
    Get full text
    Article


  15. 15

    Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. by Haneen Nur, Karel Fostier, Sandrine Aspeslagh, Wim Renmans, Elisabeth Bertrand, Xavier Leleu, Mérédis Favreau, Karine Breckpot, Rik Schots, Marc De Waele, Els Van Valckenborgh, Elke De Bruyne, Thierry Facon, Dirk Elewaut, Karin Vanderkerken, Eline Menu

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  16. 16

    The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse by Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Emma Verheye, Elina Alaterre, Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne

    Get full text
    Article


  17. 17

    Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy by Eline Menu, Lorenzo Franceschini, Karin Vanderkerken, Elke De Bruyne, Karine Breckpot, Kim De Veirman, Arne Van der Vreken, Fabien Thery, Chenggong Tu, Kevin Mwangi, Sofie Meulewaeter, Lien De Beck, Edith Janssens, Francis Impens, Rein Verbeke, Ine Lentacker

    Published in Journal for ImmunoTherapy of Cancer (2025-04-01)
    Get full text
    Article


  18. 18

    Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia by Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman

    Published in Blood Cancer Journal (2023-12-01)
    Get full text
    Article


  19. 19

    Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma by Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman

    Published in Journal for ImmunoTherapy of Cancer (2023-01-01)
    Get full text
    Article


  20. 20

    RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma by Martina Emde-Rajaratnam, Susanne Beck, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose

    Published in Frontiers in Immunology (2023-11-01)
    Get full text
    Article


Search Tools: